Skip to main content
. Author manuscript; available in PMC: 2021 Aug 16.
Published in final edited form as: J Orthop Res. 2019 Feb 21;37(6):1310–1317. doi: 10.1002/jor.24209

Table 1.

Media supplementation by treatment group

Group Media Supplementation
rhBMP-2 (100 ng/mL for 2 days, 50 ng/mL following) Complete DMEM with 170μM ascorbic acid, 2 mM β-glycerol phosphate (βGP)
scAAV-equine-BMP-2 Complete DMEM with 170 μM ascorbic acid, 2 mM β-glycerol phosphate (βGP)
scAAV-GFP Complete DMEM with 170 μM ascorbic acid, 2 mM β-glycerol phosphate (βGP)
Osteogenic Control Complete DMEM with 170μM ascorbic acid, 2 mM β-glycerol phosphate (βGP), 1 × 10−9 M dexamethasone
Negative Control Complete DMEM with 170 μM ascorbic acid, 2 mM β-glycerol phosphate (βGP)
Expansion Media Complete αMEM with 4 ng/mL recombinant FGF-2